The Short Answer
This page lists the hematology hospitals in our directory offering Multiple Myeloma Treatment in UAE, including Burjeel Hospital for Advanced Surgery Dubai, Kings College Hospital Dubai, Aster Hospital Dubai. Each listing links through to the hospital's full profile page.
Ask us about multiple myeloma treatment in UAE
Share a few details and our care coordination team will get back to you with next steps.
Top Hospitals for Multiple Myeloma Treatment in UAE
🇦🇪 Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE 4.5 (1 reviews) 209 beds
Why consider this hospital?
4.5/5 rating from 1 reviews209 beds
Specialties & Accreditation
OrthopedicsCardiac SciencesCosmetic SurgeryGastroenterologyGeneral SurgeryGynecology
Hospit — Hospital Certificates of Services accreditation
View full profile →Patients considering multiple myeloma treatment can be cared for by Burjeel Hospital for Advanced Surgery Dubai's care team in Dubai, UAE, from initial consultation through recovery. Burjeel Hospital for Advanced Surgery Dubai, accredited by Hospital Certificates of Services, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.
4.5/5
Rating
2014
Established
209
Beds
Dubai, UAE
Location
🇦🇪 Kings College Hospital Dubai
Dubai, UAE 4.5 (1 reviews) 100 beds
Why consider this hospital?
4.5/5 rating from 1 reviews100 beds
Specialties & Accreditation
Cardiac SciencesCosmetic SurgeryENTGastroenterologyGeneral SurgeryGynecology
Hospit — Hospital Certificates of Services accreditation
View full profile →Patients considering multiple myeloma treatment can be cared for by Kings College Hospital Dubai's care team in Dubai, UAE, from initial consultation through recovery. Kings College Hospital Dubai, accredited by Hospital Certificates of Services, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.
4.5/5
Rating
2014
Established
100
Beds
Dubai, UAE
Location
🇦🇪 Aster Hospital Dubai
Dubai, UAE 4.5 (1 reviews) 114 beds
Why consider this hospital?
4.5/5 rating from 1 reviews114 beds
Specialties & Accreditation
BariatricCardiac SciencesCosmetic SurgeryENTGastroenterologyGeneral Surgery
JCI — Joint Commission International accreditation
View full profile →Patients considering multiple myeloma treatment can be cared for by Aster Hospital Dubai's care team in Dubai, UAE, from initial consultation through recovery. Aster Hospital Dubai, accredited by JCI, follows recognised patient-safety and quality-of-care standards when performing multiple myeloma treatment.
4.5/5
Rating
1987
Established
114
Beds
Dubai, UAE
Location
Top Hematology Doctors in UAE
FeaturedMr. Aadil Rashid Wani
Specialist In-Patient Rehabilitation & Musculoskeletal · Specialty: Hematology
Burjeel Medical City, Abu Dhabi Abu Dhabi, UAE16+ Years experience
Why consider this doctor?
- 16+ years of experience in Hematology
- In-charge Physiotherapist, BGS Gleneagles Global Hospitals, Bangalore – 10 years
- Chief Physiotherapist, Brains Neuro Spine Hospitals, Bangalore – 6 years
Hematology Experience: 16+ YearsHospital Affiliation: Burjeel Medical City, Abu Dhabi
Dr. Mariam Al Mansoori
Medical Degree, Rheumatology Fellowship
Specialist Internal Medicine (Rheumatology & Immunology) · Specialty: Hematology
Burjeel Medical City, Abu Dhabi Abu Dhabi, UAE10+ Years experience
Why consider this doctor?
- 10+ years of experience in Hematology
- Chief Fellow, Rheumatology Fellowship, National Institute for Health Specialties (NIHS), 2023–2024
Expertise & Procedures
- Musculoskeletal ultrasound
- Joint injections
Hematology Experience: 10+ YearsHospital Affiliation: Burjeel Medical City, Abu Dhabi
Dr. Mohamed Ibrahim
Medical Doctorate in Anesthesia and Intensive Care, Master's degree in Anesthesia and Intensive Care
Consultant Anesthesia & Pain Medicine · Specialty: Hematology
Burjeel Medical City, Abu Dhabi Abu Dhabi, UAE20+ Years experience
Why consider this doctor?
- 20+ years of experience in Hematology
Expertise & Procedures
- Radiofrequency ablation (conventional, pulsed, cooled) on medial and lateral branches
- Dorsal root ganglion radiofrequency
- Peripheral nerve radiofrequency
- Regenerative medicine using platelet-rich plasma (PRP)
- Bone marrow aspirate for musculoskeletal pain
Hematology Experience: 20+ YearsHospital Affiliation: Burjeel Medical City, Abu Dhabi
Dr. Rim AL Choughri
Bachelor of Medicine, Master's degree in Pediatrics
Specialist Pediatrics · Specialty: Hematology
Burjeel Medical City, Abu Dhabi Abu Dhabi, UAE20+ Years experience
Why consider this doctor?
- 20+ years of experience in Hematology
- Specialist Pediatrician, Burjeel Medical City, Abu Dhabi
- Pediatric practitioner in healthcare facilities in Syria and UAE
Hematology Experience: 20+ YearsHospital Affiliation: Burjeel Medical City, Abu Dhabi
Our Methodology
How we selected these hospitals
A hospital appears on this page when Hematology is among its listed specialties and it is located in UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
What To Look For
How to Select the Best Hospital for Multiple Myeloma Treatment in UAE?
Choosing the right hospital for multiple myeloma treatment is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include hematology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Clinical Overview
Understanding Multiple Myeloma Treatment
Multiple Myeloma is a malignancy of plasma cells in the bone marrow, and modern treatment protocols — including VRd (Bortezomib, Lenalidomide, Dexamethasone) induction, Autologous Stem Cell Transplantation (ASCT), and Daratumumab-based regimens — have transformed it from a rapidly fatal disease into a manageable, often remission-sustaining condition, with 5-year survival rates exceeding 55–60% in transplant-eligible patients at high-volume centers.
21–45 days (ASCT phase requires 3–4 weeks inpatient; induction cycles are outpatient-based but require local stay)
Hospital Stay
8–14 weeks from start of induction to safe air travel post-ASCT engraftment; induction-only patients may fly after 4–6 weeks
Total Stay in Country (Fit-to-Fly)
55–65% 5-year overall survival in transplant-eligible patients; Complete Response (CR) rates of 30–45% with VRd induction; ≥Very Good Partial Response (VGPR) rates of 70–80% with Daratumumab-VRd quadruplet therapy
Success Rate
Clinical Overview
- Multiple Myeloma (MM) is a clonal plasma cell neoplasm in which malignant plasma cells proliferate within the bone marrow, crowding out normal hematopoietic cells and producing dysfunctional monoclonal immunoglobulins (M-protein or paraprotein).
- This pathological cascade results in the hallmark CRAB criteria: hyperCalcemia, Renal insufficiency (from cast nephropathy and light-chain deposition), Anemia (normocytic, normochromic due to marrow infiltration), and Bone lesions (osteolytic lesions driven by RANKL-mediated osteoclast activation and suppressed osteoblast activity).
- Beyond CRAB features, patients frequently present with recurrent infections due to humoral immunosuppression, peripheral neuropathy, and fatigue.
Who is a Candidate?
- ELIGIBILITY FOR TRANSPLANT-ELIGIBLE PATHWAY (VRd → ASCT → Maintenance):
- Age typically ≤70 years (physiological age assessed over chronological age; fit patients up to 75 may qualify after geriatric oncology evaluation)
- Confirmed diagnosis of symptomatic Multiple Myeloma per IMWG 2014 criteria (presence of CRAB criteria or SLiM criteria: ≥60% clonal plasma cells, sFLC ratio ≥100, >1 focal lesion on MRI)
- ECOG Performance Status 0–2
- +24 more
Treatment Options & Approaches
- INDUCTION THERAPY — VRd (STANDARD TRIPLET) AND DARA-VRd (QUADRUPLET, PREFERRED FOR HIGH-RISK OR FIT PATIENTS):
Recovery
- PHASE 1 — PRE-TREATMENT WORKUP AND PLANNING (Weeks 1–2): Upon arrival, GAF Healthcare coordinates same-day or next-day specialist consultation with a dedicated Myeloma Program hematologist/oncologist.
- All diagnostic tests listed (bone marrow biopsy, FISH cytogenetics, PET-CT/WBCT, ECHO, PFTs, SPEP/IFE, sFLC, full biochemistry) are completed within 5–7 business days at the hospital.
- R-ISS staging is determined, transplant eligibility is formally assessed by a multidisciplinary tumor board (hematology, transplant physician, cardiology, nephrology), and a personalized treatment plan — including regimen selection (VRd vs.
Risks to be aware of
- Multiple Myeloma treatment with VRd, ASCT, and Daratumumab carries a spectrum of procedure-specific and drug-specific risks that patients must understand prior to initiating therapy.
- ASCT-related mortality at experienced high-volume centers is now <1–2% (Treatment-Related Mortality, TRM), but the procedure carries significant morbidity during the aplastic phase.
Why GAF Healthcare
- GAF Healthcare provides comprehensive end-to-end non-medical support designed specifically for the complexities of a prolonged oncology treatment journey involving multiple hospital phases, outpatient cycles, and extended country stays.
Common questions about Multiple Myeloma Treatment
What is the cost of Multiple Myeloma Treatment (VRd, ASCT, and Daratumumab) in India vs. the UAE?
The total cost of a complete Multiple Myeloma treatment episode — including VRd or Dara-VRd induction chemotherapy, peripheral blood stem cell mobilization and apheresis, high-dose Melphalan conditioning, Autologous Stem Cell Transplantation (ASCT), BMT unit hospitalization, supportive medications, and standard post-transplant monitoring — ranges from approximately USD 18,000 to USD 45,000 in India, depending on the specific regimen (VRd vs. quadruplet Dara-VRd), the number of induction cycles, response assessments required, and any complications during the ASCT phase. The same treatment in the UAE (Dubai or Abu Dhabi) costs approximately USD 45,000 to USD 95,000, reflecting premium hospital infrastructure, higher drug acquisition costs for imported branded biologics (Daratumumab branded as Darzalex is significantly more expensive in the UAE than in India, where domestic pricing controls and biosimilar availability reduce costs substantially), and higher facility overheads. India offers 50–65% cost savings while maintaining equivalent clinical outcomes at JCI and NABH-accredited transplant centers performing hundreds of ASCTs annually. The UAE offers premium-tier facilities with DHA and JCI accreditation, particularly advantageous for patients from GCC countries who prefer proximity, Arabic-language services, and luxury clinical environments. GAF Healthcare provides detailed cost projections for each individual patient after reviewing their diagnostic reports and proposed treatment plan, ensuring full cost transparency before any commitment.
How long do I need to stay in the country before I am fit to fly home after Multiple Myeloma treatment?
The required in-country stay depends on which phase of treatment is being undertaken. For patients receiving induction chemotherapy only (VRd or Dara-VRd without ASCT — applicable to transplant-ineligible patients or those deferring transplant), a minimum stay of 4–6 weeks is required to complete the first 2 induction cycles and confirm initial response and tolerability, after which the patient may return home and continue maintenance therapy locally with remote follow-up via GAF Healthcare's telemedicine service. For patients undergoing the full VRd induction + ASCT pathway, the total mandatory in-country stay is significantly longer: approximately 10–14 weeks (approximately 2.5 to 3.5 months). This breaks down as: 6–8 weeks for induction chemotherapy (outpatient, local stay required), 1 week for stem cell mobilization and apheresis, 3–4 weeks of inpatient hospitalization for ASCT conditioning and engraftment, and a further 4–6 weeks of post-ASCT outpatient monitoring before fit-to-fly clearance is granted. Patients are declared fit to fly at approximately Day +60 to Day +90 post-ASCT, provided the following criteria are met: stable neutrophil engraftment (ANC >1.0 × 10⁹/L), platelet count >75 × 10⁹/L without transfusion support, no active infection or fever, resolution of significant mucositis and GI complications, ability to self-administer oral medications, and availability of an equivalent standard of emergency hematological care at the home destination. Long-haul flights with prolonged immobility carry a VTE risk — LMWH prophylaxis for flights exceeding 4 hours is routinely recommended for all myeloma and post-ASCT patients. GAF Healthcare's medical coordinator manages all fit-to-fly certifications, airline communication for medical assistance requirements, and coordination with the home country physician for seamless handover.
What is the success rate of Multiple Myeloma treatment with VRd, ASCT, and Daratumumab?
Multiple Myeloma response rates and long-term outcomes have improved dramatically over the past decade with modern triplet and quadruplet regimens. The key outcome benchmarks at high-volume centers in India and the UAE are as follows: With VRd induction (3–4 cycles), approximately 70–80% of patients achieve at least a Very Good Partial Response (VGPR), and 30–45% achieve a stringent Complete Response (sCR) or Complete Response (CR) before transplant. The addition of Daratumumab (Dara-VRd quadruplet) increases pre-transplant MRD negativity rates to approximately 70–75% (vs. 45–50% with VRd alone), as demonstrated in the PERSEUS trial (2024), representing a landmark improvement in response depth. Following ASCT with high-dose Melphalan conditioning, post-transplant sCR/CR rates reach 60–70% in patients who responded well to induction. With Lenalidomide maintenance post-ASCT, the median Progression-Free Survival (PFS) is approximately 54–66 months (4.5–5.5 years) in standard-risk patients, and 5-year Overall Survival (OS) is 55–65% across all risk groups. For standard-risk patients (no high-risk cytogenetics), 5-year OS exceeds 70–75%. For transplant-ineligible patients on Dara-Rd (MAIA trial), median PFS reached 61.9 months with OS rates of approximately 66.3% at 5 years. It is important to note that Multiple Myeloma remains an incurable disease for the vast majority of patients with current technology, but it is highly treatable and controllable, with many patients living 10+ years with excellent quality of life on sequential therapies. Patients with high-risk cytogenetics — particularly del(17p) or gain(1q21) — have shorter median PFS (typically 24–36 months) and should be counseled about clinical trial options, tandem ASCT, or early consideration of CAR-T cell therapy or bispecific antibodies at relapse. GAF Healthcare only works with centers that report outcomes aligned with or exceeding international EBMT and CIBMTR benchmarks.
Related pages
Related procedures
Other cities
Compare by country
How GAF Healthcare Assists in Choosing the Best Hospital for Multiple Myeloma Treatment in UAE
Discover the Top Hospitals for Multiple Myeloma Treatment in UAE
This page lists 3 accredited hematology hospitals in UAE, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Patient Success Story
Iraqi Family's Journey: Baby Ibrahim's Life-Saving Heart Surgery in India
Common Questions
Frequently asked questions about multiple myeloma treatment in UAE
How many hematology hospitals are listed in UAE?
3 hospitals in our UAE directory are currently listed for hematology including Multiple Myeloma Treatment.
How do you choose which hospitals to list?
A hospital appears on this page when Hematology is among its listed specialties and it is located in UAE. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How much does treatment cost in UAE?
Cost varies by hospital, city and individual case. Use our cost calculator for a personalized estimate — see the link on this page.
Which cities in UAE have hematology hospitals listed?
Dubai. Use the city links on this page to view hospitals in a specific city.
Are these hospitals internationally accredited?
Hospitals listed on this page carry accreditations including Hospital Certificates of Services, JCI — see the accreditation badge shown for each hospital below.
Can I get a treatment plan and cost estimate before I travel?
Yes. Share your medical reports with the GAF Healthcare team over WhatsApp or email, and our medical team will review them and come back with a recommended hospital, a treatment plan and an itemised cost estimate before you commit to anything.
Do you help with visa, travel and accommodation?
Yes. Once you choose a hospital, our team helps arrange the medical visa invitation letter, book accommodation near the hospital, and organise airport pickup and transport to appointments.
What support do I get during and after treatment?
Our medical team reviews your reports and stays in touch throughout your treatment journey — from the first consultation through recovery, including after you return home.
What does the "Featured" label next to a hospital's name mean?
"Featured" reflects editorial prominence on this listing, not a clinical ranking or a claim that it is the "best" hospital.
How do I get matched with the right hospital for multiple myeloma treatment?
Share your medical reports and requirements with the GAF Healthcare team, and our medical coordinators will recommend a suitable hospital from this list based on your case.
Does the listed cost cover everything?
The figures shown are an indicative planning estimate, not a final quote from a specific hospital. Our team provides a single, itemised, all-inclusive quote before you make any commitment.
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for multiple myeloma treatment in UAE.
Contact us to report an inaccuracy on this page.